secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lantheus Holdings, Inc. (LNTH)
CIK:        0001521036
Form:       8-K
Filed at:   2022-12-20T23:59:59+00:00
Accession:  0001193125-22-308803
Event type: m_and_a
Sentiment:  positive
Materiality: 0.90
Item codes: 2.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lantheus closes strategic collaboration & license agreements with POINT Biopharma for PNT-2002 and PNT-2003
--------------------------------------------------------------------------------

- Paid $250M upfront for PNT-2002 (prostate cancer therapy); $10M upfront for PNT-2003 (neuroendocrine tumor therapy).
- Potential regulatory milestones up to $281M (PNT-2002) and $34.5M (PNT-2003); sales milestones up to $1.28B and $275M, respectively.
- PNT-2002 royalties: 20% after $500M cumulative gross profit; PNT-2003 royalties: 15% of net sales.
- Agreements became effective Dec 20, 2022, after HSR waiting period expired.
- Lantheus will develop and commercialize both candidates worldwide except certain Asian countries.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1521036/000119312522308803/0001193125-22-308803-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1521036/000119312522308803/d435614d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-308803

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer